Testing a new imaging tracer for certain blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new PET/CT imaging tracer called [18F]BL40 to see if it can help spot certain types of blood cancers. It may help doctors better understand and monitor these diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have been diagnosed with one of these cancers: diffuse large B-cell lymphoma, multiple myeloma, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, or Waldenström macroglobulinemia.
- You are expected to live at least 3 more months.
- You are well enough to be up and about (able to do light activity).
- You are able to lie flat on your back for the imaging scan.
- You are not pregnant or breastfeeding, and you have no known allergies to the study tracer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
This study tests a new imaging agent that helps PET scans show cancer more clearly. It may help doctors see where cancer is in your body and plan your treatment better.
This trial tests a new imaging agent that may help doctors see tumors more clearly during a PET scan. It is for people with certain types of cancer who are willing to have a biopsy of their tumor.
This trial tests a new imaging agent that helps find cancer cells that have come back. It is given as an injection and then a scan is done to see if it helps doctors locate the cancer.
This study tests whether using PET scans and a simple blood test (called liquid biopsy) can quickly and accurately monitor how well your lymphoma is responding to standard first-line treatment. The goal is to see if these real-time monitoring tools can improve care for aggressive B-cell lymphomas.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.